CoChat

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

Open access

Published version of a preprint

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

The efficacy of virus-specific T cells in clearing pathogens involves a fine balance between antiviral and inflammatory features. SARS-CoV-2–specific T cells in individuals who clear SARS-CoV-2 without symptoms could reveal nonpathological yet protective characteristics. We longitudinally studied SARS-CoV-2–specific T cells in a cohort of asymptomatic (n = 85) and symptomatic (n = 75) COVID-19 patients after seroconversion. We quantified T cells reactive to structural proteins (M, NP, and Spike) using ELISpot and cytokine secretion in whole blood. Frequencies of SARS-CoV-2–specific T cells were similar between asymptomatic and symptomatic individuals, but the former showed an increased IFN-γ and IL-2 production. This was associated with a proportional secretion of IL-10 and proinflammatory cytokines (IL-6, TNF-α, and IL-1β) only in asymptomatic infection, while a disproportionate secretion of inflammatory cytokines was triggered by SARS-CoV-2–specific T cell activation in symptomatic individuals. Thus, asymptomatic SARS-CoV-2–infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20202617

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-SA · PubMed Central
Figure 1. Enrollment of SARS-CoV–exposed donors. (A) Confirmed cases of SARS-CoV-2 infection in Singapore, divided into imported cases (red), cases among dormitory residents (blue), and all other community cases (yellow). Black arrows indicate the dates when blood samples were taken for the study. (B) Diagram showing the number of participants that were invited and recruited into the study. Participants who completed blood donations at recruitment and at 2- and 6-wk follow-up were tested for serology of anti-NP IgG (Abbott) and sVNT-nAb (GenScript). An additional blood sample was taken at week 6 from 85 asymptomatic participants with distinct serological profiles for the analysis of SARS-CoV-2–specific T cell responses. *, Symptoms: any of fever, cough, runny nose, sore throat, shortness of breath, fatigue, muscle ache, diarrhea, or anosmia.
Figure 1. Enrollment of SARS-CoV–exposed donors. (A) Confirmed cases of SARS-CoV-2 infection in Singapore, divided into imported cases (red), cases among dormitory residents (blue), and all other community cases (yellow). Black arrows indicate the dates when blood samples were taken for the study. (B) Diagram showing the number of participants that were invited and recruited into the study. Participants who completed blood donations at recruitment and at 2- and 6-wk follow-up were tested for serology of anti-NP IgG (Abbott) and sVNT-nAb (GenScript). An additional blood sample was taken at week 6 from 85 asymptomatic participants with distinct serological profiles for the analysis of SARS-CoV-2–specific T cell responses. *, Symptoms: any of fever, cough, runny nose, sore throat, shortness of breath, fatigue, muscle ache, diarrhea, or anosmia.CC BY-NC-SA · PubMed Central
Figure 2. SARS-CoV-2–specific antibody profile shows increasing infection prevalence among dormitory residents during the study period. (A) Dormitory residents (n = 478) were tested longitudinally for serology. The percentage of donors positive for anti-NP IgG (black) and nAbs (gray) at recruitment and after 2 and 6 wk is shown; antibody-positive donors who experienced COVID-19 symptoms before (yellow) and during (red) the study are highlighted. (B) Dot plots show longitudinally the quantity of anti-NP IgG antibodies (y axis) and the percentage inhibition by virus neutralization antibodies (sVNT; x axis) in the serum of asymptomatic study participants (n = 434) at recruitment (left), after 2 wk (middle), and after 6 wk (right). The gray area marks the limit of assay detection. Spearman correlation. (C) Longitudinal anti-NP IgG levels of asymptomatic donors who were seropositive at recruitment (n = 106, left), who seroconverted at week 2 (n = 52, middle), and who seroconverted by week 6 (n = 77, right). (D) Anti-NP IgG serological profile of donors selected for SARS-CoV-2–specific T cell analysis at the 6-wk time point (n = 85). Donors with distinct antibody profiles are shown in different colors and are summarized in the table.
Figure 2. SARS-CoV-2–specific antibody profile shows increasing infection prevalence among dormitory residents during the study period. (A) Dormitory residents (n = 478) were tested longitudinally for serology. The percentage of donors positive for anti-NP IgG (black) and nAbs (gray) at recruitment and after 2 and 6 wk is shown; antibody-positive donors who experienced COVID-19 symptoms before (yellow) and during (red) the study are highlighted. (B) Dot plots show longitudinally the quantity of anti-NP IgG antibodies (y axis) and the percentage inhibition by virus neutralization antibodies (sVNT; x axis) in the serum of asymptomatic study participants (n = 434) at recruitment (left), after 2 wk (middle), and after 6 wk (right). The gray area marks the limit of assay detection. Spearman correlation. (C) Longitudinal anti-NP IgG levels of asymptomatic donors who were seropositive at recruitment (n = 106, left), who seroconverted at week 2 (n = 52, middle), and who seroconverted by week 6 (n = 77, right). (D) Anti-NP IgG serological profile of donors selected for SARS-CoV-2–specific T cell analysis at the 6-wk time point (n = 85). Donors with distinct antibody profiles are shown in different colors and are summarized in the table.CC BY-NC-SA · PubMed Central
Figure S1. Kinetics of SARS-CoV-2 nAb profile in the asymptomatic study cohort. Longitudinal levels of nAbs measured as percentage inhibition by sVNT in asymptomatic donors who were seropositive at recruitment (n = 134, left), who seroconverted at week 2 (n = 81, middle), and who seroconverted by week 6 (n = 93, right). The gray area marks the limit of assay detection.
Figure S1. Kinetics of SARS-CoV-2 nAb profile in the asymptomatic study cohort. Longitudinal levels of nAbs measured as percentage inhibition by sVNT in asymptomatic donors who were seropositive at recruitment (n = 134, left), who seroconverted at week 2 (n = 81, middle), and who seroconverted by week 6 (n = 93, right). The gray area marks the limit of assay detection.CC BY-NC-SA · PubMed Central
Figure 3. Frequency of T cells specific for different SARS-CoV-2 proteins in asymptomatic donors with distinct serological profiles. (A) SARS-CoV-2 proteome organization; analyzed proteins have a red outline and are marked by *. 15-mer peptides overlapping by 10 amino acids were split into pools covering NP1, NP2, and M and selected 15-mers covering the more T cell immunogenic regions of S. T cell reactivity was tested by ex vivo IFN-γ-ELISpot. (B) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for the asymptomatic donors with distinct serological profiles (line = median). IFN-γ-SFC ≥10/106 PBMCs were considered positive (gray area is below limit of detection). Circles below represent the percentage of a positive response (red) to the individual peptide pools, and numbers of individuals tested are stated below the circles. Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure 3. Frequency of T cells specific for different SARS-CoV-2 proteins in asymptomatic donors with distinct serological profiles. (A) SARS-CoV-2 proteome organization; analyzed proteins have a red outline and are marked by *. 15-mer peptides overlapping by 10 amino acids were split into pools covering NP1, NP2, and M and selected 15-mers covering the more T cell immunogenic regions of S. T cell reactivity was tested by ex vivo IFN-γ-ELISpot. (B) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for the asymptomatic donors with distinct serological profiles (line = median). IFN-γ-SFC ≥10/106 PBMCs were considered positive (gray area is below limit of detection). Circles below represent the percentage of a positive response (red) to the individual peptide pools, and numbers of individuals tested are stated below the circles. Wilcoxon matched-pairs signed rank test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure S2. T cells reactive to different pools of S peptides in COVID-19 convalescents. Spike is a long protein with 1,276 amino acids; thus it requires 253 15-mer peptides overlapping by 10 amino acids to cover the whole protein, equaling 7 pools of ∼40 peptides. To reduce the number of peptide pools to test, we selected a single “S pool” comprising 55 peptides. For the selection, all sequences of published SARS-CoV-1 epitopes (http://www.iedb.org; positive assays only, T cells assays, host: human) were aligned with the library of S-SARS-CoV-2 15-mers. We selected the 15-mer peptides that cover the homologue sequence of the described SARS-CoV-1 epitope sequences. In addition, we added the 15-mer peptides that cover the predicted SARS-CoV-2 S epitopes published by Grifoni et al. (2020b). The 55 peptides cover 40.5% of the S protein. The frequency of reactive cells to the selected S pool (red) was compared with the seven pools of 15-mers overlapping by 10 amino acids covering together the entire S protein (S1–S7) in COVID-19 convalescents (n = 15).
Figure S2. T cells reactive to different pools of S peptides in COVID-19 convalescents. Spike is a long protein with 1,276 amino acids; thus it requires 253 15-mer peptides overlapping by 10 amino acids to cover the whole protein, equaling 7 pools of ∼40 peptides. To reduce the number of peptide pools to test, we selected a single “S pool” comprising 55 peptides. For the selection, all sequences of published SARS-CoV-1 epitopes (http://www.iedb.org; positive assays only, T cells assays, host: human) were aligned with the library of S-SARS-CoV-2 15-mers. We selected the 15-mer peptides that cover the homologue sequence of the described SARS-CoV-1 epitope sequences. In addition, we added the 15-mer peptides that cover the predicted SARS-CoV-2 S epitopes published by Grifoni et al. (2020b). The 55 peptides cover 40.5% of the S protein. The frequency of reactive cells to the selected S pool (red) was compared with the seven pools of 15-mers overlapping by 10 amino acids covering together the entire S protein (S1–S7) in COVID-19 convalescents (n = 15).CC BY-NC-SA · PubMed Central
Figure S3. CD4+ and CD8+ T cells are reactive to stimulation with SARS-CoV-2–specific peptides. For asymptomatic donors (n = 3; <4 wk anti-NP IgG+), short-term T cell lines were generated by PBMC stimulation with the different peptide pools and a 10-d expansion protocol (Le Bert et al., 2020). A peptide pool-matrix strategy was applied that identified single T cell epitopes. Subsequently, the short-term T cell lines were restimulated for 5 h with the identified single peptides and analyzed by intracellular cytokine staining for IFN-γ. (A) The gating strategy to identify CD4+ and CD8+ T cells is shown. FSC, forward scatter; SSC, side scatter. (B) Dot plots show examples of CD4+ and CD8+ T cells producing IFN-γ in response to stimulation with three different peptides (upper panels) and the corresponding unstimulated controls (lower panels).
Figure S3. CD4+ and CD8+ T cells are reactive to stimulation with SARS-CoV-2–specific peptides. For asymptomatic donors (n = 3; <4 wk anti-NP IgG+), short-term T cell lines were generated by PBMC stimulation with the different peptide pools and a 10-d expansion protocol (Le Bert et al., 2020). A peptide pool-matrix strategy was applied that identified single T cell epitopes. Subsequently, the short-term T cell lines were restimulated for 5 h with the identified single peptides and analyzed by intracellular cytokine staining for IFN-γ. (A) The gating strategy to identify CD4+ and CD8+ T cells is shown. FSC, forward scatter; SSC, side scatter. (B) Dot plots show examples of CD4+ and CD8+ T cells producing IFN-γ in response to stimulation with three different peptides (upper panels) and the corresponding unstimulated controls (lower panels).CC BY-NC-SA · PubMed Central
Figure 4. Dynamics and hierarchy of SARS-CoV-2–specific T cells in asymptomatic and symptomatic infection. (A) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for asymptomatic SARS-CoV-2–infected donors who were serologically positive for anti-NP IgG at at least one time point during the study period (n = 72; left), for COVID-19 patients from acute to 3 mo after infection (n = 45; middle), and archived unexposed controls (n = 51; right; line = median). Circles below represent the frequency of a positive (IFN-γ-SFC ≥10/106 PBMCs) response (red) to the individual peptide pools. Repeated-measures one-way ANOVA with Greenhouse–Geisser correction, followed by Holm–Sidak’s multiple comparisons test. (B) Bar graphs show the percentage of donors reacting to the number of peptide pools tested. (C) Frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for each donor of the asymptomatic cohort (n = 72). Donors are organized according to their serological status of anti-NP IgG antibodies. (D) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown in asymptomatic donors grouped by anti-NP IgG status (anti-NP IgG positive <4 wk: n = 15; anti-NP IgG positive >6 wk: n = 33; anti-NP IgG negative <4 wk: n = 16; anti-NP IgG negative 4–6 wk: n = 8). Unpaired t test. (E) Frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for symptomatic COVID-19 patients organized by months after clearance of SARS-CoV-2 infection (n = 82). (F) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown in COVID-19 patients grouped by months after infection (acute to 1 mo: n = 28; 2–3 mo: n = 18; 4–5 mo: n = 9; 6–7 mo: n = 27). Unpaired t test. (G and H) Frequency of SARS-CoV-2 peptide–reactive cells in individuals with asymptomatic (blue) and symptomatic (red) infection during the acute phase until 1 mo after recovery (left; asymptomatic: n = 15; symptomatic: n = 28) and in convalescents 2–3 mo after infection (right; asymptomatic: n = 57; symptomatic: n = 19; G) and deconvoluted to the individual peptide pools (H). Mann–Whitney tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure 4. Dynamics and hierarchy of SARS-CoV-2–specific T cells in asymptomatic and symptomatic infection. (A) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for asymptomatic SARS-CoV-2–infected donors who were serologically positive for anti-NP IgG at at least one time point during the study period (n = 72; left), for COVID-19 patients from acute to 3 mo after infection (n = 45; middle), and archived unexposed controls (n = 51; right; line = median). Circles below represent the frequency of a positive (IFN-γ-SFC ≥10/106 PBMCs) response (red) to the individual peptide pools. Repeated-measures one-way ANOVA with Greenhouse–Geisser correction, followed by Holm–Sidak’s multiple comparisons test. (B) Bar graphs show the percentage of donors reacting to the number of peptide pools tested. (C) Frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for each donor of the asymptomatic cohort (n = 72). Donors are organized according to their serological status of anti-NP IgG antibodies. (D) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown in asymptomatic donors grouped by anti-NP IgG status (anti-NP IgG positive <4 wk: n = 15; anti-NP IgG positive >6 wk: n = 33; anti-NP IgG negative <4 wk: n = 16; anti-NP IgG negative 4–6 wk: n = 8). Unpaired t test. (E) Frequency of IFN-γ SFCs reactive to the individual peptide pools is shown for symptomatic COVID-19 patients organized by months after clearance of SARS-CoV-2 infection (n = 82). (F) The frequency of IFN-γ SFCs reactive to the individual peptide pools is shown in COVID-19 patients grouped by months after infection (acute to 1 mo: n = 28; 2–3 mo: n = 18; 4–5 mo: n = 9; 6–7 mo: n = 27). Unpaired t test. (G and H) Frequency of SARS-CoV-2 peptide–reactive cells in individuals with asymptomatic (blue) and symptomatic (red) infection during the acute phase until 1 mo after recovery (left; asymptomatic: n = 15; symptomatic: n = 28) and in convalescents 2–3 mo after infection (right; asymptomatic: n = 57; symptomatic: n = 19; G) and deconvoluted to the individual peptide pools (H). Mann–Whitney tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure 5. Cytokine secretion profile of whole-blood cultures from asymptomatic and symptomatic convalescents stimulated with SARS-CoV-2 peptide pools. (A) Schematic of whole-blood stimulation with SARS-CoV-2 peptide pools overnight and analysis of the cytokine secretion profile (after DMSO control subtraction) using unsupervised clustering algorithm UMAP. (B) UMAP plots generated with all analyzed blood culture supernatants (n = 274) with indicated cytokine secretion heatmaps. (C) Concatenated cytokine secretion profiles of peptide-pool stimulated whole blood from asymptomatic SARS-CoV-2–infected (left; blue), SARS-CoV-2–unexposed (middle; gray), and SARS-CoV-2 infected with mild (right; orange) and moderate to severe (right; red) symptoms overlaid on the global UMAP plot of all analyzed samples (black dots; each dot corresponds to one culture supernatant). Number of individuals tested are indicated above the quadrant (n); each individual was usually tested with four different peptide pools, and total tests performed are indicated within each quadrant (#). (D) The cytokine secretion profile of the samples from the asymptomatic cohort separated by donors who seroconverted to anti-NP IgG+ <4 wk before (left), who were persistently seropositive (middle), and those who lost anti-NP IgG during the 6-wk study period (right). (E) The cytokine secretion profile of the samples from the symptomatic cohort separated by donors who were in the first month (left), second month (middle), and third to fifth months (right) after SARS-CoV-2 infection. (F) The amount of indicated cytokines secreted upon whole blood stimulation with the peptide pools is compared between donors who had a recent (<4 wk ago) asymptomatic (blue; n = 11; tests # = 44) or mild (orange; n = 15; tests # = 34) or moderate to severe (red; n = 5; tests # = 12) symptomatic SARS-CoV-2 infection. Line = median concentration. Mann–Whitney tests. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure 5. Cytokine secretion profile of whole-blood cultures from asymptomatic and symptomatic convalescents stimulated with SARS-CoV-2 peptide pools. (A) Schematic of whole-blood stimulation with SARS-CoV-2 peptide pools overnight and analysis of the cytokine secretion profile (after DMSO control subtraction) using unsupervised clustering algorithm UMAP. (B) UMAP plots generated with all analyzed blood culture supernatants (n = 274) with indicated cytokine secretion heatmaps. (C) Concatenated cytokine secretion profiles of peptide-pool stimulated whole blood from asymptomatic SARS-CoV-2–infected (left; blue), SARS-CoV-2–unexposed (middle; gray), and SARS-CoV-2 infected with mild (right; orange) and moderate to severe (right; red) symptoms overlaid on the global UMAP plot of all analyzed samples (black dots; each dot corresponds to one culture supernatant). Number of individuals tested are indicated above the quadrant (n); each individual was usually tested with four different peptide pools, and total tests performed are indicated within each quadrant (#). (D) The cytokine secretion profile of the samples from the asymptomatic cohort separated by donors who seroconverted to anti-NP IgG+ <4 wk before (left), who were persistently seropositive (middle), and those who lost anti-NP IgG during the 6-wk study period (right). (E) The cytokine secretion profile of the samples from the symptomatic cohort separated by donors who were in the first month (left), second month (middle), and third to fifth months (right) after SARS-CoV-2 infection. (F) The amount of indicated cytokines secreted upon whole blood stimulation with the peptide pools is compared between donors who had a recent (<4 wk ago) asymptomatic (blue; n = 11; tests # = 44) or mild (orange; n = 15; tests # = 34) or moderate to severe (red; n = 5; tests # = 12) symptomatic SARS-CoV-2 infection. Line = median concentration. Mann–Whitney tests. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure S4. Cytokines produced by immune cells following stimulation with SARS-CoV-2 peptide pools. PBMCs (n = 3) were stimulated for 5 h (or 7 h for IL-6) with SARS-CoV-2 peptide pools and analyzed by intracellular cytokine staining. (A) The gating strategy to identify the different immune cell subsets is shown. FSC, forward scatter; SSC, side scatter. (B) Dot plots show examples (n = 1) of T cells producing IFN-γ, TNF-α, and IL-2 and monocytes producing IL-6 in response to stimulation with the M peptide pool (red) overlaid with the corresponding unstimulated controls (black).
Figure S4. Cytokines produced by immune cells following stimulation with SARS-CoV-2 peptide pools. PBMCs (n = 3) were stimulated for 5 h (or 7 h for IL-6) with SARS-CoV-2 peptide pools and analyzed by intracellular cytokine staining. (A) The gating strategy to identify the different immune cell subsets is shown. FSC, forward scatter; SSC, side scatter. (B) Dot plots show examples (n = 1) of T cells producing IFN-γ, TNF-α, and IL-2 and monocytes producing IL-6 in response to stimulation with the M peptide pool (red) overlaid with the corresponding unstimulated controls (black).CC BY-NC-SA · PubMed Central
Figure S5. Cytokine secretion profile of whole blood from asymptomatic and symptomatic convalescents stimulated with SARS-CoV-2 peptide pools, separated by age and SARS-CoV-2 proteins. (A) UMAP plots comparing the cytokine secretion profiles of whole blood stimulated with SARS-CoV-2 peptide pools between asymptomatic (blue) and symptomatic (orange/red) SARS-CoV-2–infected individuals (all analyzed time points after infection). Donors of both groups were divided into different age groups (20–29 yr, top; 30–39 yr, middle; 40–49 yr, bottom). The violin plots show the quantity of IFN-γ and IL-2 detected in the culture supernatants. Number of individuals tested are indicated (n); each individual was usually tested with four different peptide pools, and total tests performed are indicated (#). (B) As in A, but only for the samples collected within 1 mo after infection. (C) UMAP plots comparing the cytokine secretion profiles of whole blood from asymptomatic (blue) and symptomatic (orange/red) SARS-CoV-2–infected individuals stimulated with the four different SARS-CoV-2 peptide pools shown individually. The violin plots show the quantity of IFN-γ (left) and IL-2 (right) detected in the different culture supernatants. Mann–Whitney tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure S5. Cytokine secretion profile of whole blood from asymptomatic and symptomatic convalescents stimulated with SARS-CoV-2 peptide pools, separated by age and SARS-CoV-2 proteins. (A) UMAP plots comparing the cytokine secretion profiles of whole blood stimulated with SARS-CoV-2 peptide pools between asymptomatic (blue) and symptomatic (orange/red) SARS-CoV-2–infected individuals (all analyzed time points after infection). Donors of both groups were divided into different age groups (20–29 yr, top; 30–39 yr, middle; 40–49 yr, bottom). The violin plots show the quantity of IFN-γ and IL-2 detected in the culture supernatants. Number of individuals tested are indicated (n); each individual was usually tested with four different peptide pools, and total tests performed are indicated (#). (B) As in A, but only for the samples collected within 1 mo after infection. (C) UMAP plots comparing the cytokine secretion profiles of whole blood from asymptomatic (blue) and symptomatic (orange/red) SARS-CoV-2–infected individuals stimulated with the four different SARS-CoV-2 peptide pools shown individually. The violin plots show the quantity of IFN-γ (left) and IL-2 (right) detected in the different culture supernatants. Mann–Whitney tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure 6. Frequency and function of SARS-CoV-2 peptide pool–reactive cells. (A) The frequency of IFN-γ SFCs reactive to the peptide pools analyzed by ELISpot assay (x axis) is plotted against the amount of the cytokines secreted following whole-blood stimulation with the identical peptide pools (y axis) of the asymptomatic cohort (n = 28; tests # = 109). Samples from donors with recent SARS-CoV-2 infection (<4 wk anti-NP IgG+) are highlighted in blue. Spearman correlation. (B) The frequency of IFN-γ–secreting cells (SFC) reactive to the peptide pools analyzed by ELISpot assay (x axis) is plotted against the amount of the cytokines secreted following whole-blood stimulation with the identical peptide pools (y axis) of the symptomatic cohort (n = 37; tests # = 109). Samples from donors with recent SARS-CoV-2 infection (<4 wk PCR neg) are highlighted in red. Spearman correlation.
Figure 6. Frequency and function of SARS-CoV-2 peptide pool–reactive cells. (A) The frequency of IFN-γ SFCs reactive to the peptide pools analyzed by ELISpot assay (x axis) is plotted against the amount of the cytokines secreted following whole-blood stimulation with the identical peptide pools (y axis) of the asymptomatic cohort (n = 28; tests # = 109). Samples from donors with recent SARS-CoV-2 infection (<4 wk anti-NP IgG+) are highlighted in blue. Spearman correlation. (B) The frequency of IFN-γ–secreting cells (SFC) reactive to the peptide pools analyzed by ELISpot assay (x axis) is plotted against the amount of the cytokines secreted following whole-blood stimulation with the identical peptide pools (y axis) of the symptomatic cohort (n = 37; tests # = 109). Samples from donors with recent SARS-CoV-2 infection (<4 wk PCR neg) are highlighted in red. Spearman correlation.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 330

Metadata

Authors
Le Bert, N., Clapham, H. E., Tan, A. T., Chia, W. N., Tham, C. Y. L., Lim, J. M., Kunasegaran, K., Tan, L. W. L., Dutertre, C.-A., Shankar, N., Lim, J. M. E., Sun, L. J., Zahari, M., Tun, Z. M., Kumar, V., Lim, B. L., Lim, S. H., Chia, A., Tan, Y.-J., Tambyah, P. A., Kalimuddin, S., Lye, D., Low, J. G. H., Wang, L.-F., Wan, W. Y., Hsu, L. Y., Bertoletti, A., & Tam, C. C.
Affiliations
  • Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 1
  • National University of Singapore (SG)
  • Inserm (FR)
  • Alexandra Hospital (SG)
  • Singapore General Hospital (SG)
  • Agency for Science, Technology and Research (SG)
  • National University Hospital (SG)
Corresponding author
Bertoletti, Antonio
Venue
Journal of Experimental Medicine
Published
2021-03-01
Volume
218
Issue
5
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3134489892
Cited by
330
References
38
Citations by year
2026: 11 · 2025: 22 · 2024: 45 · 2023: 68 · 2022: 110 · 2021: 74
FWCI
23.60
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • National University of Singapore (submittedVersion)
Funders
  • National University Health System (NUHSRO/2020/052/RO5+5/NUHS-COVID/6)
  • Saw Swee Hock School of Public Health
  • National University of Singapore
  • National Research Foundation Singapore (NRF2016NRF-NSFC002-013)
  • National Medical Research Council
  • Ministry of Health - Singapore (STPRG-FY19-001, COVID19RF-003, COVID19RF3-0060)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
SARS-CoV-2, COVID-19 pandemic, asymptomatic infection, virus-specific T cells, cell-mediated immunity, interferon-gamma, interleukin-2, IL-10, inflammatory cytokines, cytokine production, spike protein, nucleocapsid protein, matrix protein, T cell activation, seroconversion
MeSH terms
COVID-19, SARS-CoV-2, Adult, Humans, Lymphocyte Activation, Male, Middle Aged, T-Lymphocytes, Cytokines, Asymptomatic Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.